Key facts
- Glory (China)’s last known valuation is $31.4M (Apr 2022).
- It has raised $3.1M; the latest was Later Stage VC in Dec 2024.
- Notable investors include Sunflower Pharmaceuticals Group, Zhongsu Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Glory (China)
- ·The full record, as it builds
Funding rounds
No funding rounds for Glory (China) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Glory (China)
Manufacturer, provider and developer of probiotic products, function food and dietary supplement intended to provide nutrition. The company also provides OEM/ODM services including personalized nutrition, marketing analysis, product planning and etc., enabling clients with probiotic products, function food and dietary supplement.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Wuxi, China
- Founded
- 2018
- Website
- glorynt.com/
- Ownership
- Privately Held (backing)
Glory (China) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Glory (China) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Glory (China) in its N-PORT filings yet. We sweep new filings monthly.